Diminished Ovarian Reserve (DOR) poses significant challenges to fertility and hormonal health, with limited effective treatments. This prospective, self-controlled clinical study evaluates the safety and efficacy of intraovarian injection of autologous Adipose-Derived Regenerative Cells (ADRCs) to improve ovarian function in reproductive-aged women with DOR.
The ARISE trail enrolled 25 women aged \<40 years meeting clinical criteria for DOR, excluding those with severe comorbidities. Autologous adipose tissue was harvested via liposuction, and ADRCs were isolated using the Celution® system before bilateral ovarian medulla injection. Participants underwent follow-up at multiple time points up to 12 months post-procedure.
Primary outcomes included cumulative clinical pregnancy rates (natural or via ART) within 12 months and 1-, 2-, 3-, 6-month changes in ovarian reserve markers (FSH, AMH, antral follicle count) in non-pregnant patients. Secondary outcomes encompassed ovarian reserve markers at 12 months, as well as menstrual pattern recovery and ovarian volume changes at 1, 2, 3, 6, 12 months. Adverse events (AEs) will be monitored at each time point.
Statistical analyses followed standard principles, including mixed models for repeated measures and appropriate tests for subgroup comparisons. Sample size was determined based on feasibility and prior effect size estimates to ensure adequate power.
This study provides novel insights into regenerative therapies for DOR, emphasizing safety and functional restoration.
Female patients aged 20-39 years.
Diagnosed with DOR, defined as AFC < 7 and/or AMH ≤ 1.1 ng/mL.
FSH ≤ 40 U/L.
Have signed informed consent for the clinical trial.
Presence of thyroid disorders.
Body Mass Index (BMI) < 18 kg/m².
Confirmed pregnancy (positive β-hCG with ultrasound confirmation of embryo implantation).
History of autoimmune diseases.
Cytori Therapeutics
Lead sponsor
Peking University People's Hospital
Collaborator